Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The ...

Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...

AnaptysBio, Inc. (NASDAQ:ANAB) shareholders should be happy to see the share price up 13% in the last month. But that cannot eclipse the less-than-impressive returns over the last three years. In ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on Monday,RTT News reports.

AnaptysBio, Inc. (NASDAQ:ANAB) shareholders should be happy to see the share price up 13% in the last month. But that cannot eclipse the less-than-impressive returns over the last three years. In fact ...

Shares of AnaptysBio stock opened at $16.51 on Tuesday. AnaptysBio has a 52-week low of $12.51 and a 52-week high of $41.31. The firm has a market capitalization of $502.40 million and a PE ratio ...

AnaptysBio ANAB underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

San Diego-based AnaptysBio Inc. (NASDAQ: ANAB) handled the drug's research and development stage. Vanda will pay AnaptysBio a total $15 million: $10 million upfront and another $5 million for its ...

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA), on Monday, announced it has entered into an exclusive global license agreement with AnaptysBio Inc. (ANAB) for the development and commercialization ...